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Huntington’s disease (HD) is a neurodegenerative
disorder caused by a polyglutamine expansion
within Huntingtin (Htt) protein. In the phenotypic
screen we identified a class of quinazoline-derived
compounds that delayed a progression of a motor
phenotype in transgenic Drosophila HD flies. We
found that the store-operated calcium (Ca2+) entry
(SOC) pathway activity is enhanced in neuronal cells
expressing mutant Htt and that the identified
compounds inhibit SOC pathway in HD neurons.
The same compounds exerted neuroprotective
effects in glutamate-toxicity assays with YAC128
medium spiny neurons primary cultures. We demon-
strated a key role of TRPC1 channels in supporting
SOC pathway in HD neurons. We concluded that
the TRPC1-mediated neuronal SOC pathway consti-
tutes a novel target for HD treatment and that the
identified compounds represent a novel class of
therapeutic agents for treatment of HD and possibly
other neurodegenerative disorders.
INTRODUCTION
Huntington’s disease (HD) is an inherited autosomal dominant
neurodegenerative disorder caused by a polyQ expansion (>36
glutamine repeats) in Huntingtin (Htt) protein (Huntington’s
Disease Collaborative Research Group, 1993). The pathological
hallmark of HD is the loss of medium spiny neurons (MSN) in the
striatum, which accounts for the major clinical symptoms of the
disease. The clinical picture of HD include chorea, psychiatric
disturbance, gradual dementia, and death (Vonsattel and
DiFiglia, 1998). The exact cause of striatal neuronal loss in HD
remains elusive. Diverse pathological paradigms of HD have
been proposed such as transcriptional dysregulation, oxidative
stress, mitochondrial dysfunction, ubiquitin-proteasome systemChemistry & Biology 18,impairment, and aberrant caspase activation (Cha, 2007; Gil and
Rego, 2008; Imarisio et al., 2008; Petrucelli and Dawson, 2004;
Roze et al., 2008; Zhang et al., 2006). Growing evidence has
suggested that abnormalities in Ca2+ signaling play an important
role in pathogenesis of HD (Bezprozvanny, 2009; Tang et al.,
2005). Dopamine signaling antagonist tetrabenazine (selective
VMAT2 inhibitor) has been recently approved by the Food and
Drug Administration for treatment of HD symptoms in the United
States (Bezprozvanny, 2009; Huntington Study Group, 2006).
There is no disease-modifying therapy currently available to
prevent the onset of HD symptoms or slow the progression of
the disease.
The usual approach to drug discovery is based on developing
drugs against previously validated targets, but the target-based
approach has not been successful in developing HD therapeu-
tics so far. Another approach is based on phenotypic screens
in animal models of the disease. The advantage of phenotypic
screening strategy is that it facilitates discovery of potential
hits without prior assumptions about pathogenic mechanisms
and in the context of the biological complexity that in vitro and
cell-based models cannot easily achieve (Marsh et al., 2009).
To identify potential HD therapeutic agents, we established
a phenotypic screen by taking an advantage ofDrosophila trans-
genic HD model that has been previously described (Al-Ramahi
et al., 2006). In our experiments a small molecule quinazoline-
derived compound library was screened for compounds that
were able to delay progression of a motor phenotype in trans-
genic flies after induction of human Htt-128Q fragment expres-
sion. As a result of the screen we identified a number of hits
that alleviated phenotype of transgenic HD flies.
Evaluation of obtained hits revealed that the same compounds
have been previously isolated as inhibitors of nuclear factor-kB
(NF-kB) pathway activation in immune cells (Tobe et al.,
2003b). It has been previously suggested that these compounds
do not inhibit NF-kB directly but act by blocking store-operated
calcium (Ca2+) entry (SOC) (Choi et al., 2006), a critical step
upstream of NF-kB activation in immune cells. An importance
of SOC pathway for neuronal physiology was highlighted in
recent studies of STIM2 knockout mice (Berna-Erro et al.,
2009), genetic studies in Drosophila (Hasan and Venkiteswaran,777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 777
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SOC Pathway in HD2010; Venkiteswaran and Hasan, 2009) and in recent functional
studies with neuronal cultures (Gruszczynska-Biegala et al.,
2011). In our studies we evaluated activity of isolated
compounds as SOC inhibitors in HD neurons and validated their
neuroprotective effects in experiments with MSN cultures from
YAC128 transgenic mice. We discovered that the neuroprotec-
tive effects observed inDrosophilaHD and YAC128MSN assays
were well correlated with ability of these compounds to inhibit
activity of NF-kB and SOC pathways. We also discovered that
neuronal SOC pathway is significantly upregulated in mutant
Huntingtin expressing neurons. Based on these results we
concluded that SOC pathway constitute a novel therapeutic
target for treatment of HD and possibly other neurodegenerative
disorders.
RESULTS
EVP4593 Is an NF-kB Pathway Inhibitor Isolated
in the Phenotypic Screen with Drosophila HD
Transgenic Model
Photoreceptor-specific expression of the exon 1-4 fragment of
a human huntingtin gene with 128Q expansion in Drosophila
has been reported to result in a neurodegenerative phenotype
(Al-Ramahi et al., 2006). We discovered that expression of the
same Htt-128Q transgene under control of pan-neuronal
promoter leads to progressively impaired motor performance
of transgenic HD flies with limb tremors and decreased climbing
speed. The motor phenotype developed by transgenic HD flies
can be quantified by dropping the flies to the bottom of the
tube and measuring the speed of upward climbing for individual
flies. On average the speed of upward climbing was reduced
from 12 mm/s immediately after transgene expression to
5mm/s 10 days after eclosion (Figure 1A, blue line). The climbing
speed of control flies expressing LacZ transgene remained
constant at 13 mm/s in the same time period (Figure 1A, red
line). To validate this experimental system, we reconfirmed
efficacy of several pharmacological compounds published in
the previous studies withDrosophilaHDmodels, such as histone
deacetylase inhibitor inhibitors TSA (Figure 1A, green line)
and SAHA (data not shown) and rapamycin (data not shown)
(Ravikumar et al., 2004; Steffan et al., 2001). Thus, we concluded
that the reproducible, progressive and quantifiable motor
deficit observed in transgenic HD flies (Figure 1A) provides an
opportunity for screening for novel potential HD therapeutic
agents.
In search for such agents we screened a quinazoline-derived
small molecule library composed of 521 compounds using the
climbing assay as readout and identified several initial hits. The
initial hits were used in a structure similarity search and
a secondary focused library of additional 72 quinazoline-derived
compounds was generated and screened. As a result of the
secondary focused library screening we discovered EVP4593
as a potent hit. This compound significantly slowed the progres-
sive decline in the climbing speed of the HD flies (Figure 1A,
yellow line). The efficacy of EVP4593 at 400 mM in the climbing
assay was superior to the efficacy of TSA at 250 mM (Figure 1A),
which was used as a positive control in our experiments (Steffan
et al., 2001). The efficacy of TSA at 400 mM could not be tested
because of toxicity observed at TSA concentrations above778 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 Elsevier250 mM (data not shown). To quantify the effects of EVP4593,
we measured an average improvement in the climbing speed
when compared to HD transgenic flies feed with 1% dimethyl
sulfoxide (DMSO). To calculate a magnitude of the observed
effects, the difference in the average climbing speed of HD flies
resulting from EVP4593 feeding was normalized to the standard
deviation in the climbing speed of the entire DMSO-treated
group.When the data collected during days 8–10 after transgene
induction were averaged, we determined that feeding the flies
with 400 mM of EVP4593 resulted in an average effect size of
3.0 (p < 0.003) (Figure 1B). The efficacy of EVP4593 was dose-
dependent in the range between 100 mM and 400 mM in the fly
food (Figure 1B). The EVP4593 had no significant effect on climb-
ing performance of HD flies at 50 mM (Figure 1B). The EVP4593
had no toxic effects onDrosophila in the range of concentrations
tested in our assays (50–400 mM).
EVP4593 is a derivative of 6-aminoquinazoline class (Fig-
ure 1C) that has been previously isolated as an inhibitor of
PMA/PHA-induced NF-kB pathway activation in Jurkat cells
(Tobe et al., 2003b). To determine if the beneficial effects
observed in the climbing assay with transgenic HD flies (Fig-
ure 1A) are related to inhibition of NF-kB signaling, we selected
seven structural analogs of EVP4593 from the same chemical
class (Figure 1C). The efficacy of each of these compounds
was evaluated in the climbing assay with HD flies and in PMA/
PHA-induced NF-kB assay with human Jurkat cells. The effect
size in the climbing assay was measured in the presence of
200 mM of each tested compound in the fly food at days 8–10
after Htt-128Q transgene induction. The inhibition of NF-kB acti-
vation was evaluated at 1 mM of each compound. We found that
EVP4593, EVP14782, and EVP14756 demonstrated significant
potency in climbing assay with effect sizes in the range of 2–4
(p < 0.003) (Figure 1D). In contrast, EVP14809, EVP14810,
EVP14812, and EVP14808 compounds were inactive in the
climbing assay (Figure 1D). When evaluated in NF-kB assay,
compounds EVP4593, EVP14782, and EVP14756 were also
most potent with 50%–60% inhibition (Figure 1D). Compounds
EVP14809 and EVP14810 were less potent with 20% inhibition
and compounds EVP14812, and EVP14808 were unable to
inhibit NF-kB activation (Figure 1D).
To get more insight into mechanism of action of these
compounds, we evaluated dose-dependence of NF-kB pathway
inhibition by these compounds. We discovered that EVP4593,
EVP14782, and EVP14756 acted as high affinity partial antago-
nists of NF-kB pathway activation. These three compounds in-
hibited 50%–60% of NF-kB activity with apparent affinities in
the nanomolar range (see Figure S1 available online; Table 1).
Compounds EVP14809 and EVP14810 also acted as partial
antagonists of NF-kB activation but with affinities in the
micromolar range (Figure S1; Table 1). The compounds
EVP14812 and EVP14808 were not able to inhibit NF-kB activa-
tion (Figure S1; Table 1). Our analysis revealed excellent correla-
tion between ability of compounds in this chemical series to
inhibit PMA/PHA-induced NF-kB activation in human Jurkat
cells and to alleviate motor symptoms developed by transgenic
HD flies (Figure 1D and Table 1). This correlation was further
confirmed by testing 30 more additional analogs from the
same chemical class with various potencies of NF-kB inhibition
(data not shown).Ltd All rights reserved
Figure 1. Identification of EVP4593 in Climbing Assay Screen with Huntington’s Disease Transgenic Flies
(A) The climbing speed of HD flies is plotted as a function of time after induction of mHtt-128Q transgene. The results with lacZ-expressing flies are shown as
a control (red). A number of small molecule compounds were dissolved in dimethyl sulfoxide (DMSO) and included in the fly food in the final concentration as
indicated. The results obtained in HD flies for 400 mM EVP4593 (orange), 250 mM TSA (green) and 1% DMSO (blue) are compared.
(B) Dose-dependence of EVP4593 in rescuing motor dysfunction of HD flies. An average effect size relative to 1% DMSO control was determined at days 8–10
after mHtt-128Q transgene induction (DSpeed), normalized to variability of the climbing speed in DMSO-treated group (s) and plotted as mean ± SE (n = 30 flies)
against concentration of EVP4593 in the fly food.
(C) Chemical structures of EVP4593 and its analogs used in the study. BMS-345541 is an unrelated compound with potent IKK inhibitory activity. 2-APB is an
unrelated compound with ability to block SOC with low affinity in some cell types.
(D) The potency of 200 mM of EVP4593 or its analogs in the climbing assay was determined as an average effect size at days 8–10 after mHtt-128Q transgene
induction and shown as mean ± SE (n = 30 flies) (filled bars). The potency of 1 mM of EVP4593 or its analogs was determined as percent inhibition of NF-kB
activity and shown as mean ± SE (n = 4–6) (open bars). Also shown are results for BMS-345541 and 2-APB (400 mM in climbing assay and 1 mM in NF-kB assay
for both compounds).
See also Figure S1.
Chemistry & Biology
SOC Pathway in HDTo determine if direct inhibition of NF-kB is responsible for
beneficial effects observed in the climbing assay, we evaluated
structurally unrelated compound BMS-345541 (Figure 1C).
BMS-345541 is a potent IkB kinase (IKK) inhibitor (Burke et al.,
2003), which fully and with high affinity suppressed PMA/PHA-
induced NF-kB activation in Jurkat cells in our experiments
(Figure 1D; Figure S1). However, BMS-345541 at 400 mM was
inactive when tested in the climbing assay with transgenic HD
flies (Figure 1D). Similarly negative results were obtained in
experiments with several additional IKK inhibitors tested in the
climbing assay with transgenic HD flies (data not shown). In
contrast, EVP4593 was not active when tested in the IKK kinase
assay (data not shown). These data suggested that direct inhibi-
tion of NF-kB may not be responsible for the beneficial effects
observed with EVP4593, EVP14782, and EVP14756 compounds
in the climbing assays.Chemistry & Biology 18,The library of quinazoline class of compounds was chosen
initially for our screen as this scaffold often leads to kinase inhib-
itors, and kinases are considered attractive and tractable drug
targets. However, when EVP4593 compound was evaluated at
10 mM concentration in commercial kinase inhibition assays
using screening platforms from MDS Pharma Services, Ambit
Biosciences, andMillipore we could not detect significant kinase
inhibitory activity for this compound (data not shown). All these
results suggested that EVP4593 and its active analogs
EVP14782 and EVP14756 are likely to inhibit NF-kB activation
indirectly. This conclusion is consistent with the partial antago-
nism displayed by these compounds when tested in PMA/
PHA-induced NF-kB activation assay (Figure S1), in contrast to
the full antagonism displayed in the same assay by BMS-
345541 (Figure S1). PMA/PHA-induced NF-kB activation
depends on activation of protein kinase C (PKC) and Ca2+ influx.777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 779
Table 1. Performance of EVP4593 and Its Analogs in Different Assays
EVP
Compound
HD Flies Climbing
Assay (200 mM)
NF-kB Inhibition
(EC50, nM)
SOC Inhibition
(Ca2+ assay, 0.3 mM)
SOC Inhibition
(Mn2+ assay, 0.3 mM)
SOC Inhibition
(Ephys assay, 0.3 mM)
In Vitro HD Assay
(0.03–3.0 mM)
14782 + 7 ND + ND +
4593 + 9 + + + +
14756 + 66 + + ND +
14809  1150 ND ND ND +/
14810  1203 ND  ND 
14812  8934 ND  ND 
14808  >10,000    
Ephys, electrophysiological; HD, Huntington’s disease; ND, not determined; SOC, store-operated calcium current.
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SOC Pathway in HDWe determined that EVP4593 does not inhibit PKC in in vitro
kinase assays (data not shown). Thus, we hypothesized that
EVP4593 may act by inhibiting store-operated Ca2+ entry
(SOC), a critical upstream step of NF-kB activation in Jurkat
cells. Indeed, it has been previously reported that EVP4593
can inhibit SOC in experiments with SH-5Y5 cells (Choi et al.,
2006). To test this possibility, we evaluated structurally distinct
2-APB compound (Figure 1C) that is known to act as low affinity
SOC inhibitor in some cells (Bootman et al., 2002; Ma et al.,
2003). We discovered that when added to fly food at 400 mM,
2-APB also demonstrated significant benefit in the climbing
assay (Figure 1D). Interestingly, at 1 mM concentration 2-APB
did not inhibit NF-kB activation (Figure 1D), indicating that
SOC pathway in Jurkat cells is not efficiently blocked by
2-APB. Based on these results we proposed that EVP4593 and
its active analogs EVP14782 and EVP14756 might exert
beneficial effect by inhibiting SOCCa2+ entry pathway in neurons
of HD flies. To test this hypothesis we set out to determine if
EVP4593 and its active analogs act by inhibiting SOC pathway
in neuronal cells.
EVP4593 and Its Active Analogs Inhibit Store-Operated
Ca2+ Entry in HD Striatal Neurons
In our studies, we focused on medium spiny striatal neurons
(MSN), the main locus of pathology in HD. In the first series of
experiments we evaluated the size of SOC in wild-type (WT)
MSN and YAC128 MSN. The WT and YAC128 MSN were incu-
bated in Ca2+-free media in the presence of 1 mM of SERCA
pump inhibitor thapsigargin (Tg) for 5 min to cause complete
depletion of intracellular Ca2+ stores. After complete store deple-
tion the neurons were transferred to the extracellular media
containing 2 mM Ca2+ and the amplitude of initial cytosolic
Ca2+ influx after Ca2+-re-addition was determined by Fura-2
imaging. In these experiments we observed that the amplitude
of SOC Ca2+ entry was significantly higher in YAC128 MSN
(Figure 2B) than in WT MSN (Figure 2A). On average, the ampli-
tude of SOC Ca2+ entry was 0.21 ± 0.02 (n = 38) in WT MSN and
0.30 ± 0.02 (n = 29) in YAC128 MSN (p < 0.05) (Figure 2E). We
also found the thapsigargin-induced Ca2+ release from the ER
was reduced in YAC128 MSN when compared with WT (Figures
2A and 2B). Most likely this is due to increased sensitivity of
InsP3R1 to activation by InsP3 caused by the presence of the
mutant Htt (Tang et al., 2003), which causes increased ER
Ca2+ leakage at the steady-state conditions. Addition of780 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 Elsevier300 nM of EVP4593 resulted in strong attenuation of SOC Ca2+
influx in YAC128 MSN neurons (Figure 2D). On average the
amplitude of SOC Ca2+ entry in YAC128 MSN was reduced
from 0.30 ± 0.02 (n = 29) in the presence of DMSO control to
0.11 ± 0.02 (n = 54) in the presence of 300 nM of EVP4593 (p <
0.001) (Figure 2E). Similar suppression of SOC Ca2+ entry was
also observed in the presence of 300 nM EVP14756 (Figure 2E).
In contrast, inactive analog EVP14808 had no effect on the
amplitude of SOC Ca2+ entry in YAC128 MSN cells when tested
in the same concentration (Figure 2E). Interestingly, SOC
pathway in WT neurons was much less sensitive to inhibition
by EVP4593. Addition of 300 nM EVP4593 did not inhibit Ca2+
increase in WT neurons (Figure 2C) and had no significant effect
on the amplitude of SOC-mediated Ca2+ elevation inWT neurons
(Figure 2E).
To quantitatively compare ability of EVP4593 and its analogs
to inhibit SOC pathway in YAC128 MSN, we performed a series
of measurements using Mn2+-induced Fura-2 quenching
method (Dadsetan et al., 2008; Yang et al., 2005). In our exper-
iments YAC128 MSN were loaded with Fura-2 and incubated in
Ca2+-free media in the presence of 30 mM of SERCA pump
inhibitor CPA for 10 min to completely deplete Ca2+ stores
and to activate SOC pathway. After addition of 150 mM Mn2+
to the extracellular solution, Fura-2 quenching was initiated
and initial slope of the F360 decline was measured (Figure 3A,
section a). Five minutes later 1& DMSO control or test
compounds in 300 nM concentration were added and the
rate of Fura-2 quenching was measured again (Figure 3A,
section b). The effect of test compounds on SOC activity was
estimated by comparing the slope of Fura-2 Mn2+ quenching
before (Figure 3A, section a) and after (Figure 3A, section b)
addition of the compounds for each cell. In these experiments
we found that an addition of DMSO had no effect on the rate of
Fura-2 Mn2+ quenching (Figure 3A). In contrast, addition of
EVP4593 resulted in significant reduction in the rate of Fura-2
Mn2+ quenching (Figure 3B). The inactive analog EVP14808
had no significant effect on the Fura-2 Mn2+ quenching rate
(Figure 3C). To compare results obtained in different experi-
ments, we calculated the ratio of the Fura-2 Mn2+ quenching
rates observed after (phase b) and before (phase a) addition
of the test compounds to each cell. From this analysis we
determined that EVP4593, EVP14756 and EVP14782
compounds inhibited SOC pathway activity by 40% when
tested at 300 nM (Figure 3D and Table 1). In contrast, inactiveLtd All rights reserved
Figure 2. Store-Operated Calcium Pathway in Wild-Type and YAC128 MSNs-Ca2+ Imaging Assay
(A and B)WT (A) and YAC128 (B) medium spiny neurons (MSN) cultures at DIV10–14were loadedwith Fura-2 Ca2+ imaging dye and incubated in Ca2+-freemedia.
The intracellular Ca2+ stores were depleted by addition of 1 mM of thapsigargin (Tg) as indicated. Re-addition of 2 mM Ca2+ to the extracellular media resulted in
Ca2+ influx via SOC pathway. Fura-2 340/380 ratio traces are shown for individual cells (gray thin lines). For each cell 340/380 ratio trace was offset to 0.0 for the
time point of Ca2+ re-addition. The average trace is also shown (black thick line).
(C and D) SOC Ca2+ imaging experiments were performed with WT (C) and YAC128 (D) MSN in the presence of 300 nM EVP4593.
(E) An average amplitude of an increase in 340/380 Fura-2 signals in response to Ca2+ re-addition is shown for YAC128 andWTMSN in the presence of DMSO or
300 nM of test compounds as indicated. The results are shown as mean ± SE (number of cells is shown on the top of the bar). *p < 0.05; ***p < 0.001 when
compared to DMSO group. ns, nonsignificant.
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SOC Pathway in HDanalogs EVP14808 and EVP14810 had no significant effect on
SOC activity (Figure 3D and Table 1) and EVP14812 appeared
to increase the rate of Fura-2 Mn2+ quenching (Figure 3D andChemistry & Biology 18,Table 1). The EVP14809 caused interference with the Mn2+
quenching assay and the potency of this compound could
not be evaluated by this approach.777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 781
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Figure 3. SOC Pathway in YAC128 MSNs-Mn2+ Quenching Assay
(A–C) SOC pathway in YAC128 MSN is quantified by Mn2+ quenching assay. The YAC128 MSNs loaded with Fura-2 were placed in Ca2+-free and Mn2+-free
media containing 100 mM EGTA. The intracellular Ca2+ stores are depleted by 10 min incubation with 30 mM of CPA. After addition of 150 mM of Mn2+ to the
extracellular media the Fura-2 quenching is quantified as reduction of the Fura-2 fluorescent signal at isobestic lex = 360 nM (F360). The rate of Fura-2 Mn
2
quenching is calculated as the slope of the curve and determined for each cell before (phase a) and after (phase b) addition of DMSO (A), 300 nMof EVP4593 (B) or
300 nM EVP14808 (C). Fura-2 F360 traces are shown for individual cells (gray thin lines). For each cell F360 signal was normalized to F360 signal at the time point of
Mn2+ addition. The average trace is also shown (black thick line).
(D) The changes in Fura-2 Mn2+ quench rates in YAC128 MSNs are plotted as b/a slope ratios for each compound tested at 300 nM concentration. The average
b/a ratios for each compound are shown as mean ± SE (number of cells is indicated above each bar). ***p < 0.001 when compared with DMSO group.
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SOC Pathway in HDEVP4593 Inhibits TRPC1-Supported SOC Ca2+ Currents
in Neuronal Cells
To further evaluate an ability of EVP4593 to act as SOC inhibitors
we performed a series of electrophysiological experiments. In
initial experiments we attempted whole cell recordings of SOC
currents in primarymouseMSN cultures. Wewere able to record
thapsigargin-activated Ba2+ currents in mouse MSN cultures at
the magnitude of 1.0 ± 0.2 (n = 10) pA/pF (data not shown).
However, these experiments were technically difficult and it
was challenging to obtain stable SOC recordings inMSN primary
cultures. Thus, for electrophysiological analysis we selected
SK-N-SH human neuroblastoma cells transiently transfected
with human Htt-15Q or Htt-138Q expression constructs. The
Htt expression constructs were cotransfected with EGFP782 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 Elsevierplasmid and transfected cells were identified by GFP fluores-
cence. In whole cell recordings of Isoc activity we used 10 mM
Ba2+ as a charge carrier as we previously described for A431
cells (Gusev et al., 2003). Under these conditions, passive store
depletion after addition of 1 mM thapsigargin (Tg) induced inward
cation currents that reached the maximum within 3 min after
addition of Tg (Figure 4A). In these experiments we found that
amplitude of Isoc inward currents in nontransfected cells and
in the cells transfected with Htt-15Q cells was practically
indistinguishable (Figure 4A). At –80 mV holding potential the
amplitude of maximal Isoc currents in both groups of cells was
equal to 0.45 pA/pF (Figures 4A–4C). In contrast, Tg-induced
Isoc currents in Htt-138Q cells were much larger (Figure 4A),
with maximal currents reaching 2.3 pA/pF at 80 mV (FiguresLtd All rights reserved
Figure 4. Recordings of Isoc in SK-N-SH Cells
Transfected with Htt-15Q and Htt-138Q
(A) The amplitude of Isoc currents recorded in whole-cell
experiments are shown as a function of time after appli-
cation of 1 mM Tg (indicated by arrow) to nontransfected
SK-N-SH cells (Ctrl, green triangles) and to SK-N-SH cells
transiently transfected with Htt-15Q (red squares) or Htt-
138Q (black circles). The amplitude of Isoc currents for all
groups of cells was measured every 10 s at 80 mV test
potential. Data from representative experiments are shown.
(B) The average current-voltage relationships recorded
after full development of Isoc in nontransfected SK-N-SH
cells (Ctrl, green trace) and SK-N-SH transiently trans-
fected with Htt-15Q (red trace), or Htt-138Q (black trace).
Each trace is an average based on a number of experi-
ments as indicated in (C).
(C) The average Isoc amplitude in nontransfected SK-N-SH
cells (Ctrl) and in SK-N-SH transfected with Htt-15Q or Htt-
138Q constructs. For all groups of cells Isoc amplitude was
determined at –80 mV test potential and plotted as mean ±
SE (n = number of experiments). ***p < 0.001 when
compared to Htt138Q-transfected cells.
(D) Isoc currents in nontransfected SK-N-SH cells (Ctrl) and
SK-N-SH cells transfected with Htt-138Q plasmid are
shown as a function of the time after 1 mM Tg application
(indicated by arrow). The representative data obtained in
the presence of DMSO (blue triangles for nontransfected
cells and black circles for transfected cells), 300 nM
EVP4593 (red squares for transfected cells and cyan
rhombs for nontransfected cells), and 300 nM EVP14808
(green triangles for transfected cells) are shown. The
amplitude of Isoc currents for all groups of cells was
measured every 10 s at80 mV test potential. The times of
EVP4593, EVP14808 and DMSO applications are shown
above the Isoc plot.
(E) The average current-voltage relationships recorded
after full development of Isoc in nontransfected SK-N-SH
cells (Ctrl) and in SK-N-SH transfected with Htt-138Q in the
presence of DMSO (blue trace for control cells and black
trace for transfected cells), 300 nM EVP4593 (cyan trace for
control cells and red trace for transfected cells), and
300 nM EVP14808 (green trace). Each trace is an average
based on a number of experiments indicated in (F).
(F) The average Isoc amplitude in nontransfected (Ctrl) SK-
N-SH cells and in SK-N-SH cells transfected with Htt-138
and recorded in the presence of DMSO, 300 nM EVP4593
or 300 nM EVP14808. For all groups of cells Isoc amplitude
was determined at –80 mV test potential and plotted as
mean ± SE (n = number of experiments). ***p < 0.001 when
compared to Htt138Q-transfected cells in the presence of
DMSO.
Chemistry & Biology
SOC Pathway in HD4A–4C). On average, the amplitude of Isoc currents in SK-N-SH
cells transfected with Htt-138Q plasmid was five times larger
than in nontransfected cells or in the cells transfected with
Htt-15Q plasmid (Figure 4C). The increased Isoc activity in elec-
trophysiological experiments with neuronal cells transfected
with Htt-138Q plasmid is consistent with increased SOC activity
that we observed in Ca2+ imaging experiments with YAC128
MSNs (Figure 2).
To investigate the ability of EVP4593 to inhibit Isoc currents in
SK-N-SH cells transfected with Htt-138Q, we applied 300 nM
EVP4593 to the cells after Tg-induced Isoc current was fully acti-
vated. We found that addition of EVP4593 resulted in immediateChemistry & Biology 18,block of Isoc currents in these cells (Figure 4D). After washout of
EVP4593 the amplitude of the Isoc current was partially recov-
ered (Figure 4D), indicating that the inhibition was reversible. In
contrast, addition of 300 nM EVP14808 had no effect on Isoc
current in Htt-138Q transfected cells, similar to addition of
DMSO carrier solution alone (Figure 4D). Addition of 300 nM
EVP4593 resulted in 2.5-fold reduction in the magnitude of
Isoc currents recorded at 80 mV holding potential in
Htt-138Q-transfected cells (Figures 4D–4F). In contrast, addition
of the same concentration of EVP14808 had no significant effect
on Isoc currents in Htt-138Q-transfected cells (Figures 4D–4F).
The small Isoc current in nontransfected SK-N-SH cells was777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 783
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SOC Pathway in HDsensitive to EVP4593 (Figure 4D), but to a far lesser extent than
Isoc current in Htt-138Q-transfected cells (Figures 4D–4F). This
conclusion is consistent with results obtained in Ca2+ imaging
experiments with WT and YAC128 MSN (Figure 2).
Themolecular composition of neuronal SOC pathway is poorly
understood, with potential components including members of
mammalian Trp family and Orai1 channels (Berna-Erro et al.,
2009; Gruszczynska-Biegala et al., 2011; Hasan and Venkites-
waran, 2010; Putney, 2003; Venkiteswaran and Hasan, 2009).
Our electrophysiological measurements indicate that the chan-
nels upregulated in SK-N-SH cells in response to Htt-138Q
transfection are relatively nonselective (Figure 4B), consistent
with the known properties of mammalian TRPC channels
(Montell, 2005). It has been recently demonstrated that together
with Orai channels TRPC channels play an important role in sup-
porting SOC in Jurkat cells (Wenning et al., 2011), and it is
possible that EVP4593 inhibited TRPC-supported currents in
our NF-kB activation experiments (Figure 1D). TRPC1 channels
are expressed in the nervous system (Riccio et al., 2002) and
we reasoned that TRPC1 subunits may play a role in supporting
Isoc currents upregulated in response to Htt-138Q expression.
To test this hypothesis, we cotransfected SK-N-SH cells with
Htt-138Q plasmid and siRNA plasmid against human TRPC1
subunit. Off-target control siRNA was used as a negative control
in these experiments. Expression of endogenous TRPC1 in
SK-N-SH cells and the efficiency of siRNA-mediated TRPC1
knockdown in transfected cells were confirmed by western blot-
ting of cellular lysates (Figure S2). In these experiments we found
that RNAi-mediated knockdown of TRPC1 significantly reduced
Tg-induced Isoc currents in Htt-138Q-transfected cells (Fig-
ure 5A). At –80 mV holding potential the amplitude of Isoc
currents in these cells was equal to 0.8 pA/pF, comparable to
the amplitude of Isoc currents in nontransfected cells (Figures
5A, 5C, and 5D). On average, cotransfection of Htt-138Q with
TRPC1 RNAi plasmid reduced amplitude of Isoc currents by
70% (Figure 5D). The effect of TRPC1 RNAi was specific, as
cotransfection of Htt-138Q with control RNAi had no effect on
the amplitude of Isoc currents (Figures 5A, 5C, and 5D). In addi-
tional experiments we demonstrated that knockdown of TRPC1
by siRNA occluded effects of EVP4593 on Isoc currents in
Htt138-transfected cells (Figures 5B–5D). These experiments
pointed to TRPC1 as one of the subunits of Isoc channels
activated in response to Htt-138Q expression in SK-N-SH cells
and inhibited by EVP4593. In additional experiments we demon-
strated that RNAi-mediated knockdown of TRPC1 subunit in
primary mouse MSN cultures causes significant reduction in
the amplitude of thapsigargin-evoked SOC currents (data not
shown).
To test the hypothesis that EVP4593 blocks TRPC1-supported
channels, we transfected SK-N-SH cells with a mouse TRPC1
expression plasmid. Consistent with the known role of TRPC1
(Clapham et al., 2001), Isoc currents were significantly enhanced
in TRPC1-transfected SK-N-SH cells, similar in size to Isoc
currents in Htt-138Q-transfected cells (Figure 5A). However,
the properties of Isoc currents in TRPC1-transfected cells were
different from the properties of Isoc currents in Htt-138Q-trans-
fected cells. The shape of the current-voltage relationship in
TRPC1-transfected cells was different, withmuch larger outward
current than in Htt138Q-transfected cells (Figure 5C). Even more784 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 Elsevierstrikingly, currents resulting from TRPC1 overexpression were
not sensitive to inhibition by EVP4593 (Figures 5B and 5D).
From these experiments we concluded that EVP4593 does not
target TRPC1 homomeric channels but rather targets hetero-
meric channels containing TRPC1 as one of the subunits.
Western blotting experiments also indicated that the levels of
TRPC1 expression remain constant in Htt-138Q-transfected
SK-N-SH cells (Figure S2). Future experiments will be required
to identify the subunit of SOC channels that is upregulated in
Htt-138Q-transfected cells and forms heteromeric channels
with TRPC1.
EVP4593 and Its Active Analogs Protect YAC128 MSN
from Glutamate Toxicity
Do EVP4593 and its analogs exert neuroprotective effects in
mammalian model of HD? To answer this question we evaluated
activity of EVP4593 and its analogs in glutamate toxicity experi-
ments with primary MSN cultures from YAC128 mice. In the
previous studies we described that YAC128 MSN are signifi-
cantly more susceptible to glutamate-induced apoptosis than
WT MSN cultures (Tang et al., 2005). The difference between
glutamate-induced apoptosis of YAC128 and WT MSN is signif-
icant and consistent, providing a quantitative basis for the in vitro
HD assay. In the previous studies we took an advantage of this
experimental system to evaluate potential neuroprotective
effects of a number of clinically relevant compounds (Wu et al.,
2006, 2008, 2009). As in previous studies we determined that
in the absence of glutamate, 5%–15% of neurons were
apoptotic in both WT and YAC128 MSN cultures (Figure 6 and
Table 2). After addition of 250 mM glutamate, the fraction of
apoptotic WTMSN was increased to 30%–45% and the fraction
of apoptotic YAC128MSNwas increased to 65%–80% (Figure 6
and Table 2). The potential neuroprotective effects of EVP4593
and its analogs in our experiments were evaluated at 30 nM,
300 nM, and 3 mMconcentrations. In all experiments compounds
were added to MSN cultures 30 min before addition of gluta-
mate. We found that EVP4593 significantly protected YAC128
MSN from glutamate toxicity at 30 nM and 300 nM concentra-
tions (Figures 6A and 6B and Table 2). EVP14756 was equally
potent, with significant protective effects at 30 nM and 300 nM
concentrations (Table 2). EVP14782 was not effective at 30 nM
but was protective at 300 nM concentration (Table 2).
EVP4593, EVP14756, and EVP14782 became cytotoxic when
tested in 3 mM concentrations (Table 2). The neurons detached
in experiments with 3 mM of EVP4593 and EVP14782 and data
could not be collected, whereas for EVP14756 the toxicity
compromised its neuroprotective effect when tested at 3 mM
concentration (Table 2). EVP14809 was not effective at 30 nM
and 300 nM concentrations, but demonstrated significant neuro-
protective effects at 3 mM (Figure 6D and Table 2). EVP14808,
EVP14810, and EVP14812 were inactive at any concentrations
that were tested (Figure 6C and Table 2). From these results
we concluded that when tested in YAC128 MSN excitotoxicity
model, EVP4593, EVP14756, and EVP14782 exhibited neuro-
protective effects in nanomolar concentrations, EVP14809 was
active in micromolar concentration, and EVP14808, EVP14810,
and EVP14812 were inactive (Table 1).
Our electrophysiological data suggested that EVP4593 inhibits
TRPC1-supported SOC currents and that TRPC1-supportedLtd All rights reserved
Figure 5. TRPC1 Supports Isoc Currents in
SK-N-SH Cells Transfected with Htt-138Q
(A) The amplitude of Isoc currents recorded in
whole-cell experiments is shown as a function of
time after application of 1 mM Tg (indicated by
arrow) to SK-N-SH cells transiently transfected
with scrambled siRNA (Ctrl+ctrl siRNA, black
circles), to SK-N-SH cells transiently transfected
with TRPC1 plasmid (Ctrl TRPC1+, cyan rhombs),
to SK-N-SH cells transiently transfected with
TRPC1-RNAi (Ctrl TRPC1, green pentagons), to
SK-N-SH cells transiently cotransfected with
Htt-138Q and scrambled siRNA (yellow squares)
or to SK-N-SH cells cotransfected with Htt-138Q
and TRPC1-RNAi (dark yellow triangles).
(B) The amplitude of Isoc currents recorded in
whole-cell experiments are shown as a function of
time after application of 1 mM Tg (indicated by
arrow) to nontransfected SK-N-SH cells treated
with DMSO (Ctrl, red circles), to SK-N-SH cells
transiently transfected with TRPC1 and treated
with 300 nMEVP4593 (Ctrl TRPC1+, pink rhombs),
to SK-N-SH cells transiently transfected with
TRPC1-RNAi and treated with 300 nM EVP4593
(Ctrl TRPC1, blue pentagons), to SK-N-SH cells
cotransfected with Htt-138Q and TRPC1-RNAi
and treated with DMSO (navy triangles) or to
SK-N-SH cells cotransfected with Htt-138Q and
TRPC1-RNAi and treated with 300 nM EVP4593
(purple squares). The times of EVP4593 and
DMSO applications are shown above the Isoc plot.
On (A) and (B) the amplitude of the Isoc currents
for all groups of cells was measured every 10 s
at80 mV test potential. Data from representative
experiments are shown for each group of cells.
(C) The average current-voltage relationships
recorded after full development of Isoc in
nontransfected SK-N-SH cells (Ctrl, red trace), in
SK-N-SH cells transfected with TRPC1-RNAi and
treated with DMSO (yellow trace) or 300 nM
EVP4593 (blue trace), in SK-N-SH cells trans-
fected with Htt-138Q and treated with DMSO
(black trace), in SK-N-SH cells transfected with
TRPC1 and treated with DMSO (gray trace), in
SK-N-SH cells cotransfected with Htt-138Q and
TRPC1-RNAi and treated with DMSO (navy trace), and in SK-N-SH cells cotransfected with Htt-138Q and TRPC1-RNAi and treated with 300 nMEVP4593 (purple
trace). Each trace is an average based on a number of experiments indicated in (D).
(D) The average Isoc amplitude in SK-N-SH cells transfected with scrambled siRNA, in nontransfected SK-N-SH cells treated with DMSO, in SK-N-SH cells
transfected with TRPC1-RNAi with andwithout treatment with 300 nMEVP4593, in SK-N-SH cells transfected with TRPC1-cDNAwith and without treatment with
300 nM EVP4593, in SK-N-SH cells cotransfected with Htt-138Q and scrambled siRNA, and in SK-N-SH cells cotransfected with Htt-138Q and TRPC1-RNAi
untreated, treated with DMSO or treated with 300 nM EVP4593. For all groups of cells Isoc amplitude was determined at –80 mV test potential and plotted as
mean ± SE (n = number of experiments).
See also Figure S2.
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SOC Pathway in HDSOC currents are upregulated in response to mutant Httexp
expression (Figure 5). To confirm that neuroprotective effects of
EVP compounds are indeed due to inhibition of TRPC1-sup-
ported SOC currents, we evaluated neuroprotective effects of
TRPC1 RNAi knockdown in YAC128 MSN cultures. In these
experiments, expression of mouse TRPC1 was suppressed by
application of Dicer-mediated approach. The mixture of siRNA
(25–27 nt in size) targeting mouse TRPC1 was generated as
described in Experimental Procedures and transfected into WT
andYAC128MSNat secondday in vitro (DIV2) togetherwith non-
targeting siRNA. In parallel experiments the cells were treatedChemistry & Biology 18,with transfection reagent (PEI) alone or together with nontarget-
ing siRNA (Ctrl siRNA). In the absence of glutamate, 10%–
25% of neurons were apoptotic in both WT and YAC128 MSN
cultures (Figures 6E and 6F and Table 2) in these experiments.
The fractions of apoptotic WT and YAC128 MSN treated with
nontargeting siRNA increased slightly as a result of transfection
procedure (Figure 6E and Table 2), but they were not significantly
different from those of WT and YAC128 MSN treated with the
transfection reagent alone (Figure 6E and Table 2). After addition
of 250 mM glutamate, the fraction of apoptotic WT MSN in trans-
fection reagent control was increased to 30%–40% and the777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 785
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Figure 6. Compounds from EVP4593 Series
or Knockdown of TRPC1 Protect YAC128
MSNs from Glutamate-Induced Apoptosis
The fraction of TUNEL-positive nuclei is plotted
against glutamate concentration for MSN fromWT
(open circles) and YAC128 (YAC, filled circles)
mice. The results in the absence (black symbols)
and presence (red symbols) of compounds or
treatments are compared. The data are shown for
(A) 0.03 mMof EVP4593; (B) 0.3 mMof EVP4593; (C)
3 mM of EVP14808; (D) 3 mM of EVP14809; (E)
treatment with nontargeting RNAi reagent; and (F)
treatmentwith TRPC1RNAi. In experiments shown
in (A–D) the compounds were added 30min before
the application of glutamate. In experiments shown
in (E) and (F) neurons were transfected by RNAi at
DIV2–4. For each data point the fraction of TUNEL-
positive nuclei is shown as mean ± SE (n = 6–8
microscopic fields, 100–300 MSN per field).
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SOC Pathway in HDfraction of apoptotic YAC128MSN in transfection reagent control
was increased to 65% (Figures 6E and 6F and Table 2). The
results obtained in cells with nontargeting siRNA were identical
to results in cells exposed to transfection reagent alone (Figure 6E
and Table 2). In contrast, YAC128 MSN treated with TRPC1
siRNA were significantly protected from glutamate-induced
apoptosis when compared to transfection reagent control (Fig-
ure 6F and Table 2). The fraction of apoptotic WT MSN treated
with TRPC1 siRNA was also slightly decreased, but effect was
not significant when compared to transfection reagent control
(Figure 6F and Table 2). From these experiments we concluded
that RNAi-mediated knockdown of TRPC1 subunit protects
YAC128 MSN neurons from glutamate-induced apoptosis.786 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reservedDISCUSSION
In this study, we utilized a phenotypic
drug screening platform based on
a Drosophila transgenic HD model to
search for potential HD therapeutics.
Drosophila has been widely used to
model HD and other polyglutamine
expansion disorders, revealing several
conserved cellular pathways important
for pathogenesis (Marsh et al., 2009). In
several previous studies pharmacological
agents alleviated phenotypes developed
by Drosophila HD models (Desai et al.,
2006; Ravikumar et al., 2004; Steffan
et al., 2001). The Drosophila HD model
used in our study expressed first four
exons of human Huntingtin with 128Q
expansion under control of an inducible
promoter (Al-Ramahi et al., 2006). After
induction of Htt-128Q transgene expres-
sion in the nervous system, the HD flies
developed progressive motor phenotype
that can be quantified by using auto-
mated climbing assay (Figure 1A). By
taking advantage of this reproduciblephenotype, we developed a medium-throughput screening plat-
form for discovery of potential HD therapeutics.
We used the developed screening platform to screen a library
of quinazoline-derived compounds and after secondary round of
screening identified a compound EVP4593 as a potent hit
(Figures 1A and 1B). The same compound has been previously
isolated as an inhibitor of PMA/PHA-induced NF-kB pathway
activation in Jurkat cells (Tobe et al., 2003b). In our studies we
compared a relative efficacy of EVP4593 and its six structure-
related analogs (Figure 1C) in Drosophila HD climbing assay
and PMA/PHA-induced NF-kB activation assay in Jurkat cells.
We observed an excellent correlation between relative potencies
demonstrated by all seven compounds in these assays
Chemistry & Biology
SOC Pathway in HD(Figure 1D and Table 1). Several previous studies suggested that
NF-kB pathway might play a direct role in HD pathogenesis.
Inhibition of NF-kB activity decreased the striatal lesion in acute
excitotoxicity model (Nakai et al., 2000; Qin et al., 1998, 2001).
NF-kB activation has been observed in PC12 cells transfected
with mutant Huntingtin construct, in R6/2 transgenic HD mice
and in HD knock-in mice (Khoshnan et al., 2004; Sugars et al.,
2004). The mutant huntingtin has been shown to bind IKK,
enhancing IKK activity (Khoshnan et al., 2004). The Httexp-medi-
ated cell death in HEK293 cells and striatal slices can be rescued
by blocking IKK activity (Khoshnan et al., 2004). Recent studies
revealed that IKK can phosphorylate Htt directly and affect its
turnover rate (Thompson et al., 2009). All these results suggest
that inhibition of NF-kB pathway may provide a potential
approach for neuroprotection in HD (Chu et al., 2007).
However, further examination of isolated compounds indi-
cated that the inhibition of NF-kB pathway is not likely to be
directly responsible for the beneficial effects observed in exper-
iments with transgenic HD flies. Structurally unrelated potent IKK
and NF-kB inhibitor BMS-345541 was not effective in the climb-
ing assay with HD flies (Figure 1D). Similarly negative results
were obtained in experiments with several additional IKK inhibi-
tors that were tested (data not shown). In contrast to the fully
potent inhibitor BMS-345541, EVP4593 and its active analogs
acted as partial antagonists of NF-kB pathway (Figure S1),
consistent with indirect mode of action of these compounds.
Moreover, EVP4593 failed to block IKK or PKC directly or exhibit
any kinase inhibitory activity in a variety of screening platforms
(data not shown). Based on this analysis we hypothesized that
EVP4593 may act by inhibiting SOC, which is critical for PMA/
PHA-induced NF-kB activation in Jurkat cells. Indeed, it has
been previously reported that EVP4593 can inhibit SOC in exper-
iments with SH-5Y5 cells (Choi et al., 2006). In a series of Ca2+
imaging and electrophysiological experiments we demonstrated
that SOC pathway is upregulated in primary MSN neurons from
YAC128 transgenic HD mice (Figure 2) and in SK-N-SH human
neuroblastoma cells transfected with Htt-138Q expression
plasmid (Figure 4). The upregulation of SOCpathwaywas specif-
ically induced by Httexp and did not occur in SK-N-SH cells trans-
fected with Htt-15Q plasmid (Figure 4). Previous studies demon-
strated that the mutant Httexp affects Ca2+ signaling in MSN by
increasing the sensitivity of InsP3R1 to InsP3 (Tang et al.,
2003), by potentiating function of NR2B-containing NMDAR
(Chen et al., 1999; Fan et al., 2007; Milnerwood and Raymond,
2007; Sun et al., 2001; Zeron et al., 2002; Zhang et al., 2008),
and by destabilizing mitochondrial Ca2+ handling (Choo et al.,
2004; Panov et al., 2002). The increase in SOC pathway activity
observed in our experiments (Figure 2 and Figure 4) may be
a direct result of Httexp expression or may correspond to
a compensatory response of the cells to destabilized Ca2+
signaling. Future studies will be required to address this issue.
Consistent with the previous results (Choi et al., 2006), we
demonstrated that EVP4593 effectively inhibited SOC pathway
in YAC128 MSN (Figure 2 and Figure 3) and in SK-N-SH cells
transfected with Htt-138Q (Figure 4). The inactive analog
EVP14808 failed to inhibit SOC pathway in either experimental
system (Figures 2–4). Interestingly, EVP4593 was much less
potent in inhibiting SOC in WT MSN (Figure 2) or in nontrans-
fected SK-N-SH cells (Figure 4). These results indicate that theChemistry & Biology 18,target of EVP4593 is upregulated in neuronal cells in response
to mutant Httexp expression. In our studies we observed an
excellent correlation between ability of compounds in this series
to alleviate phenotype of transgenic HD flies in the climbing
assay, to inhibit PMA/PHA-induced NF-kB activation in
Jurkat cells and to block SOC in neuronal cells expressing Httexp
(Table 1).
Themolecular composition of neuronal SOC pathway is poorly
understood, with potential components that include members of
mammalian Trp family and Orai1 channels (Berna-Erro et al.,
2009; Gruszczynska-Biegala et al., 2011; Hasan and Venkites-
waran, 2010; Putney, 2003; Venkiteswaran and Hasan, 2009).
The current-voltage relationship of Isoc current in Htt138Q-
transfected SK-N-SH cells (Figure 4B) was consistent with rela-
tively nonselective Ca2+ channels such as Trp channels and not
with highly-selective Ca2+ channels such as Orai1. In our exper-
iments, we demonstrated that RNAi-mediated knockdown of
TRPC1 subunit significantly reduced the size of Isoc currents
in Htt-138Q-transfected SK-N-SH cells (Figure 5) and in primary
mouseMSN neurons (data not shown). We further demonstrated
that RNAi-mediated knockdown of TRPC1 occluded ability of
EVP4593 to block Isoc currents in Htt138-transfected SK-N-SH
cells (Figure 5). From these experiments we concluded that
TRPC1 is likely to be one of the subunit of SOC channels upregu-
lated in response to Htt-138Q expression and inhibited by
EVP4593. However, EVP4593 failed to inhibit Isoc currents
supported by overexpressed TRPC1 (Figure 5). From these
experiments, we concluded that EVP4593 does not target
TRPC1 homomeric channels but rather targets heteromeric
channels containing TRPC1 as one of the subunits. Consistent
with this hypothesis, we found that the levels of TRPC1 expres-
sion remain constant in Htt-138Q-transfected SK-N-SH cells
(Figure S2). Future experiments will be required to identify the
subunit of SOC that is upregulated in YAC128 MSNs and in
Htt-138Q-transfected cells and forms heteromeric channels
with TRPC1.
These experiments suggested that the channels containing
TRPC1 subunit might play a significant role in pathogenesis of
HD. TRPC1 channels have been previously implicated in excito-
toxic cell death of hippocampal neurons (Narayanan et al., 2008).
Our conclusions are further supported by recent genetic studies.
By using the same fly HD model and climbing assay as used in
our study (Figure 1A) it was recently demonstrated that
knockout of TRP subunit in Drosophila resulted in clear
beneficial effects (Al-Ramahi et al., 2010). Our conclusion is
also consistent with emerging role played by Trp familymembers
in variety of neurological disorders (Selvaraj et al., 2010;
Yamamoto et al., 2007). Mutations in TRPML1 channels cause
lysosomal storage neurodegenerative disorder mucolipidosis
type IV (Slaugenhaupt, 2002; Venkatachalam et al., 2008).
Recent studies reported that point mutations in TRPV4 channels
are linked to hereditary motor and sensor neuropathies in
humans (Auer-Grumbach et al., 2010; Deng et al., 2010;
Landoure et al., 2010) and the gain-of-function point mutation
in TRPC3 channel causes loss of cerebellar Purkinje neurons in
the moonwalker mice (Becker et al., 2009). A potential impor-
tance of Trp channels in Parkinson’s disease (PD) and in
Alzheimer’s disease (AD) has been also been previously dis-
cussed (Selvaraj et al., 2010; Yamamoto et al., 2007).777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 787
Table 2. Effects of Drugs and Treatments on Glutamate-Induced Apoptosis in WT and YAC128 MSN
EVP Compound (conc)a
WT
(% TUNEL-positive)
YAC128
(% TUNEL-positive)
0 mM Glutamate 250 mM Glutamate 0 mM Glutamate 250 mM Glutamate
4593
0.03 mM 6.75 ± 1.40
(8.98 ± 2.20)
52.37 ± 6.51
(47.07 ± 2.69)
9.12 ± 2.20
(9.09 ± 1.69)
52.81 ± 3.85b
(81.30 ± 2.76)
0.3 mM 6.91 ± 1.50
(8.65 ± 1.68)
20.28 ± 1.22b
(34.84 ± 3.98)
7.88 ± 1.61
(6.55 ± 0.78)
21.86 ± 2.20b
(71.89 ± 6.05)
3.0 mM — — — —
14756
0.03 mM 7.49 ± 2.16
(12.38 ± 2.98)
36.68 ± 4.24
(40.70 ± 5.13)
8.08 ± 1.35
(7.96 ± 1.07)
48.94 ± 6.97b
(83.99 ± 3.61)
0.3 mM 6.89 ± 0.75
(7.85 ± 1.19)
31.99 ± 4.33
(39.55 ± 3.49)
6.78 ± 1.93
(8.32 ± 1.28)
26.70 ± 4.14b
(67.96 ± 5.69)
3.0 mM 16.43 ± 1.35
(7.85 ± 1.19)
31.62 ± 5.27
(39.55 ± 3.49)
12.13 ± 1.93
(8.32 ± 1.28)
54.71 ± 3.77
(67.96 ± 5.69)
14782
0.03 mM 5.59 ± 1.01
(12.38 ± 2.98)
34.84 ± 3.51
(40.70 ± 5.13)
8.40 ± 1.62
(7.96 ± 1.07)
75.09 ± 5.99
(83.99 ± 3.61)
0.3 mM 6.25 ± 2.00
(8.65 ± 1.68)
17.88 ± 1.50b
(34.84 ± 3.98)
6.01 ± 1.14
(6.55 ± 0.78)
30.34 ± 3.33b
(71.89 ± 6.05)
3.0 mM — — — —
14808
0.03 mM 8.76 ± 1.22
(8.98 ± 2.20)
57.43 ± 5.64
(47.07 ± 2.69)
7.10 ± 1.16
(9.09 ± 1.69)
78.33 ± 5.88
(81.30 ± 2.76)
0.3 mM 5.75 ± 1.30
(7.85 ± 1.19)
39.46 ± 4.19
(39.55 ± 3.49)
10.77 ± 2.71
(8.32 ± 1.28)
56.08 ± 4.72
(67.96 ± 5.69)
3.0 mM 5.26 ± 0.83
(6.64 ± 1.32)
37.18 ± 5.04
(39.77 ± 2.56)
5.38 ± 0.84
(5.45 ± 1.07)
75.15 ± 5.35
(81.80 ± 3.84)
14809
0.03 mM 14.93 ± 2.00
(12.38 ± 2.98)
42.95 ± 4.63
(40.70 ± 5.13)
9.31 ± 2.49
(7.96 ± 1.07)
70.96 ± 5.21
(83.99 ± 3.61)
0.3 mM 8.76 ± 3.15
(8.65 ± 1.68)
39.39 ± 4.48
(34.84 ± 3.98)
5.97 ± 0.80
(6.55 ± 0.78)
61.37 ± 9.22
(71.89 ± 6.05)
3.0 mM 6.51 ± 1.70
(6.98 ± 0.95)
46.05 ± 2.40
(44.71 ± 4.12)
5.82 ± 1.56
(7.80 ± 1.56)
53.15 ± 6.42b
(75.75 ± 2.80)
14810
0.03 mM 8.31 ± 1.17
(7.59 ± 1.51)
41.95 ± 5.49
(35.29 ± 3.89)
7.72 ± 0.96
(6.97 ± 1.71)
71.98 ± 5.16
(70.24 ± 5.17)
0.3 mM 9.37 ± 1.59
(8.98 ± 2.20)
52.73 ± 4.49
(47.07 ± 2.69)
8.49 ± 2.08
(9.09 ± 1.69)
79.37 ± 3.08
(81.30 ± 2.76)
3.0 mM 5.12 ± 0.62
(7.59 ± 1.51)
33.57 ± 4.88
(35.29 ± 3.89)
6.62 ± 1.06
(6.97 ± 1.71)
64.63 ± 4.41
(70.24 ± 5.17)
14812
0.03 mM 5.95 ± 1.59
(7.59 ± 1.51)
40.85 ± 4.61
(35.29 ± 3.89)
6.10 ± 1.16
(6.97 ± 1.71)
68.50 ± 4.62
(70.24 ± 5.17)
0.3 mM 8.97 ± 1.71
(10.67 ± 2.10)
39.16 ± 5.34
(35.90 ± 4.11)
9.15 ± 1.76
(9.28 ± 1.13)
73.68 ± 5.29
(70.27 ± 5.13)
3.0 mM 8.06 ± 1.75
(7.59 ± 1.51)
39.36 ± 3.48
(35.29 ± 3.89)
6.14 ± 0.61
(6.97 ± 1.71)
68.48 ± 6.31
(70.24 ± 5.17)
Ctrl siRNA 19.93 ± 4.24
(12.69 ± 3.19)
40.55 ± 5.35
(36.16 ± 6.51)
26.75 ± 2.77
(19.68 ± 2.34)
60.22 ± 4.19
(63.47 ± 5.87)
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Table 2. Continued
EVP Compound (conc)a
WT
(% TUNEL-positive)
YAC128
(% TUNEL-positive)
0 mM Glutamate 250 mM Glutamate 0 mM Glutamate 250 mM Glutamate
TRPC1 siRNA 12.72 ± 2.75
(12.69 ± 3.19)
28.27 ± 5.20
(36.16 ± 6.51)
11.07 ± 2.40
(19.68 ± 2.34)
36.39 ± 4.24b
(63.47 ± 5.87)
— toxic, total number of cells are much less than control; Conc, concentration; MSN, medium spiny neurons; TUNEL, terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling; WT, wild-type.
a In EVP compound experiment, the number in parenthesis is the untreated control cells in the same batch of MSN culture. In siRNA experiment, the
number is the control cells treated with transfection reagent in the same batch of culture.
b p < 0.05, compared with control cells and show protective effect.
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SOC Pathway in HDTo further evaluate therapeutic potential of identified
compounds, we evaluated neuroprotective effects of these
compounds in glutamate toxicity model with YAC128 primary
MSN cultures. In the previous studies we utilized the same
experimental system to evaluate potential neuroprotective
effects of a number of clinically relevant compounds (Wu et al.,
2006, 2008, 2009). Based on the obtained results (Figure 6 and
Table 2), we concluded that EVP4593, EVP14756, and
EVP14782 exhibited neuroprotective effects in nanomolar
concentrations, EVP14809 was active in micromolar concentra-
tion and EVP14808, EVP14810, and EVP14812 were inactive.
Overall, there was an excellent correlation between neuropro-
tective effects of these compounds in YAC128 MSN glutamate
toxicity model, ability of these compounds to block SOC and
PMA/PHA-induced NF-kB activation, and efficacy in the climb-
ing assay with HD flies (Table 1). We further established that
Dicer RNAi-mediated knockdown of mouse TRPC1 subunit in
YAC128 MSN results in significant neuroprotective effect in
glutamate toxicity model (Figure 6F and Table 2). These results
further supported hypothesis that TRPC1-mediated SOC chan-
nels can be considered as a potential target for developing novel
HD therapeutics.SIGNIFICANCE
The importance of store-operated Ca2+ entry (SOC) pathway
in neuronal function is poorly understood (Hasan and Venki-
teswaran, 2010; Putney, 2003). However, potential role of
neuronal SOC pathway in pathological conditions has been
suggested based on studies with experimental models of
AD (Herms et al., 2003; Leissring et al., 2000; Yamamoto
et al., 2007; Yoo et al., 2000), PD (Bollimuntha et al., 2005;
Selvaraj et al., 2009), cerebral ischemia (Berna-Erro et al.,
2009), and excitotoxicity (Narayanan et al., 2008). Our study
together with the recent meeting report (Al-Ramahi et al.,
2010) provide the first evidence that the SOC pathway may
also play an important role in HD. In experiments with trans-
genic Drosophila HD model, cultured MSN neurons from
YAC128 HD mouse model and SK-N-SH human neuroblas-
toma cells transfected with mutant Htt expression con-
structs we demonstrated that SOC pathway is upregulated
in HD neurons. Moreover, we demonstrated that pharmaco-
logical inhibition or genetic knockdown of TRPC1-mediated
SOC pathway protects HD neurons from toxicity. These
results provide further support to the emerging hypothesis
that deranged neuronal Ca2+ signaling plays a key role inChemistry & Biology 18,HD pathogenesis (Bezprozvanny, 2009). Based on our
results, we concluded that the TRPC1-mediated SOC path-
way constitute a novel target for potential HD treatment. In
addition, we identified a number of quinazoline-derived
compounds (EVP4593, EVP14756, and EVP14782) (Figure 1C)
with ability to block neuronal SOC. These compounds can be
used to dissect role of neuronal SOC in neuronal physiology.
The same compoundsmay also provide leads for developing
a novel class of therapeutic agents for treatment of HD and
possibly other neurodegenerative disorders. Testing these
compounds in mouse models of HD and other neurodegen-
erative disorders will help to evaluate future therapeutic
potential of these molecules.
EXPERIMENTAL PROCEDURES
Compounds
Glutamate was from Tocris. Fura-2/AM and Trichostain A (TSA) were
purchased from Sigma. EVP4593 (6-amino-4-(4-phenoxyphenethyl-amino)
quinazoline), EVP14782 (6-amino-4-(4-ethoxyphenethylamino)quinazoline),
EVP14756 (6-amino-4-(4-n-pentyloxyphenethylamino)quinazoline), EVP14809
(4-(4-chlorophenethylamino)-6-nitroquinazoline), EVP14810 (4-(3-(phenyl)pro-
pylamino)quinazoline), EVP14812 (4-(4-acetamido)-phenethylamino-6-amino-
quinazoline), and EVP14808 (6-amino-4-(2-(3-pyridyl)ethylamino)-quinazoline)
were previously described (Tobe et al., 2003a, 2003b). The compounds were
synthesized by standard organic chemistry methods (EnVivo Inc). The struc-
tures of generated compounds were confirmed by mass spectrometry and
NMR analysis (EnVivo Inc). BMS-345541 was purchased from Calbiochem
(Cat. No. 401480). All compounds were dissolved in DMSO as 10 mM stocks
for use in animal and cellular assays.
Drosophila Climbing Assay
Drosophila stocks and crosses were maintained using standard procedures at
25C, 70% relative humidity. The transgenic mutant Huntingtin line, C(1)DX y1
w1118 f1P{w+ HS-hid+}18a/P{w+mC Act5C-GFP}JMR3; P{UAS-mhtt128Q}F27B
and the pan-neuronal driver, elav-GAL4C155/Y, P{w+ HS-hid+} were used
to generate HD flies, elav-GAL4C155/P{w+mC Act5c-GFP}JMR3; P{UAS-
mhtt128Q}F27B/+ expressing first four exons of human Htt-128Q in the
nervous system of the flies as previously described (Al-Ramahi et al., 2006).
The motor function of HD flies or control flies (UAS-LacZ driven by elav-
GAL4 driver) were automatically monitored using tracking device to measure
the speed of upward climbing within 7.5 s after dropping the flies to the bottom
of the tube. This proprietary assay system and screening method have been
developed by EnVivo Inc. HD flies were treated with compounds dissolved
in a proprietary medium in concentration at 400 mM in the presence of 1%
DMSO. After induction of Htt-128Q transgene fragment expression, the flies
were dosed daily with testing compounds and motor assays were performed.
For each compound treatment, 10 flies were dispensed into each tube and as-
sayed in triplicate. To quantify the effect of the tested compounds the differ-
ence in the average climbing speed was calculated between the groups of
transgenic HD flies treated with the compound of interest and the groups777–793, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 789
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ation in the climbing speed determined for the entire DMSO-treated group,
yielding a quantitative measure of the effect size. Statistical models indicated
that in the assay conditions used (10 flies per tube, 16 tubes for one treatment
and three independent experiments), effect size of 0.5 corresponds to p value
of 0.03 and the effect size of 0.8 has a p value in the range between 0.03 and
0.003. Compounds showing an effect size >0.8 (p < 0.003) in the early time
points (days 1–7) or an effect size >1.2 in the late time points (days 8–10) after
three repeated assays were qualified as potential hits and evaluated further.
NF- kB Assays
Human Jurkat cells (clone E6-1) were acquired from American Type Culture
Collection and cultured in RPMI 1640 media (Invitrogen) supplemented with
10% FBS and 1% PS. The cells were plated at a density of 2 3 106 cells/
well in 6-well dishes and transiently transfected with 1 mg/well of pNF-kB-Luc
(Path Detect NF-kB reporter plasmid, Stratagene) using SuperFect Transfec-
tion Reagent (QIAGEN). After transfection, cells were incubated for 18 hr
and resuspended in RPMI 1640 medium without penicillin-streptomycin and
FBS, resulting in 1.75 3 105 cells/well in the 96-well plates. Compounds
were added 30 min before the addition of a combination of 50 ng/ml of PMA
(P1585, Sigma) and 100 mg/ml of PHA (L1668, Sigma). The plates were incu-
bated for 6 hr at 37C and luciferase assays were performed (Bright-Glo Lucif-
erase Assay System, Promega). Cell viability was measured by using MTS
assay (Promega) to determine the compound toxicity.
SOC Measurements
YAC128 mice (FVBN/NJ background strain) (Slow et al., 2003) were obtained
from Jackson Labs (stock number 004938). The male YAC128 mice were
crossed to WT female FVBN/NJ mice. P1-P2 pups were collected and geno-
typed by PCR. The primary cultures of MSN were established from YAC128
hemizygotes and WT pups as previously described (Tang et al., 2005). Briefly,
striata were dissected, diced, and digested with trypsin. After dissociation,
neurons were plated on poly-L-lysine (Sigma) coated, 12 mm round coverslips
(Assistent) in Neurobasal-A medium supplemented with 2% B27, 1 mM of
glutamine and penicillin-streptomycin (Invitrogen), and kept at 37C in a 5%
CO2 environment.
Ca2+ imaging experiments with 10–14 DIV MSN cultures were performed
using a DeltaRAM illuminator, an IC-300 camera, and processed by the
IMAGEMASTER PRO software (PTI, Photon Technology International) as we
previously described (Tang et al., 2005). Briefly, the MSN were loaded with
5 mM of Fura-2 AM for 45 min at 37C in artificial cerebrospinal fluid containing
140 mM of NaCl, 5 mM of KCl, 1 mM of MgCl2, 2 mM of CaCl2, and 10 mM of
HEPES pH 7.3 (ACSF). Coverslips were mounted onto a recording/perfusion
chamber (RC-26G, Warner Instruments) and positioned on the movable stage
of an Olympus (Melville) IX-70 invertedmicroscope. Images at 340 and 380 nm
excitation wavelengths were acquired every 2 s and 340/380 Fura-2 image
ratio was calculated. To determine SOC activity the cells were incubated in
Ca2+-free ACSF in the presence of 1 mM SERCA pump inhibitor thapsigargin
for 5 min and then transferred back to ACSF containing 2mMCa2+. The tested
compounds were added to the cells 10 min before transfer to 2 mM Ca2+.
Themanganese (Mn2+) quenching experiments were designed based on the
published studies (Dadsetan et al., 2008; Yang et al., 2005). In these experi-
ments, the rate of Fura-2 fluorescence quenching in the presence of extracel-
lular Mn2+ is used as a measure of SOC activity. The Fura-2 fluorescence was
measured at isosbestic plot of 360 nm, which is not affected by changes in
cytosolic Ca2+ concentration. For quenching experiments the cells were
placed in Ca2+-free ACSF and SERCA pump activity was blocked by addition
of CPA. The quenching measurements were initiated by addition of 150 mM of
Mn2+ to the extracellular media. Fura-2 fluorescent images were collected at
360 nm excitation wavelength (F360) every 6 s. The rate of the F360 decline
due to Fura-2 quenching is proportional to the rate of Mn2+ entry into the
cytosol and was used as an indicator of SOC activity. The tested compounds
were added to the cells 5 min after addition of Mn2+ solution and the rate of
Fura-2 quenching was reassessed.
Electrophysiological Assays
SK-N-SH human neuroblastoma cells (Cell Culture Collection, Institute of
Cytology, St. Petersburg, Russia) were transiently cotransfected with790 Chemistry & Biology 18, 777–793, June 24, 2011 ª2011 ElsevierHtt-15Q or Htt-138Q expression constructs and EGFP plasmid in 3:1 molar
ratio as we previously described for MSN cultures (Tang et al., 2003). For
TRPC1 knockdown experiments SK-N-SH cells were transiently cotrans-
fected with a mixture of Htt-138Q expression construct, RNAi-TRPC1 plasmid
and EGFP plasmid in 3:3:2 molar ratio. For TRPC1 overexpression experi-
ments SK-N-SH cells were transiently cotransfected with a mixture of mouse
TRPC1 construct in pcDNA3 expression vector (provided by Dr. Shmuel
Muallem, NIH) and EGFP plasmid in 1:1 molar ratio The RNAi-TRPC1 knock-
down plasmid was obtained by cloning the human TRPC1-derived sequence
into pSHAG vector and it was kindly provided to us by Dr. Leonidas Tsiokas
(University of Oklahoma Health Sciences Center) (Bai et al., 2008). The
efficiency of TRPC1 knockdown was confirmed by western blotting of
SK-N-SH cellular lysates with anti-TRPC1 polyclonal antibodies (1:200,
Alomone Labs, #ACC-010). The transfected cells were identified by GFP fluo-
rescence and the SOC currents were measured 48 hr after transfection using
whole-cell recordings as previously described for A431 cells (Gusev et al.,
2003). Briefly, whole-cell recordings were performed using an Axopatch
200B patch clamp amplifier (Axon Instruments). Resistance of sylgard-coated,
fire-polished glass microelectrodes was 3–5 MU. Series resistance was not
compensated. The pipette solution contained (in mM) 145 NMDG aspartate,
10 Cs-EGTA, 10 Cs-HEPES pH 7.3, 1.5 MgCl2, 4 Na2ATP, 0.4 Na2GTP, and
4.8 CaCl2 (pCa 7.0). Extracellular solution contained (in mM) 140 NMDG aspar-
tate, 10 BaCl2, 10 Cs-HEPES, 0.01 Tetrodotoxin (Alomone Labs, Israel),
0.01 Nifedipine (Sigma Aldrich, USA) pH 7.3. For the store depletion thapsigar-
gin (1 mM, Sigma Aldrich,) was used. During recording the currents were
sampled at 5 kHz and filtered digitally at 500 Hz. pClamp6 software suite
(Axon Instruments) was used for data acquisition and analysis. In all whole-
cell experiments the holding potential was 40 mV. Periodically (once every
5 s) the membrane potential was stepped to 100 mV (for 30 ms) and
a 170ms voltage ramp to +70mVwas applied. Traces recorded before current
activation were used as a template for leak subtraction. The recorded currents
were normalized to the cell capacitance. Mean value of cell capacitance was
15 ± 4 pF (n = 55).
The primary cultures of striatal medium spiny neurons (MSN) were estab-
lished fromWTmice pups (were collected at postnatal days 1–2) as described
above for Ca2+ imaging experiments. Shuttle plasmid construct encoding
shRNA against TRPC1 were obtained from Sigma Aldrich (MN_011643).
Lenti-antiTRPC1 viruses were generated by cotransfection of shuttle vector
with HIV-1 packaging vector 8.9 and VSVG envelope glycoprotein plasmids
into the packaging cell line HEK293T as we previously described (Tang
et al., 2009). Lenti-antiTRPC1 virus was added to MSN culture at DIV6 and
the whole-cell patch-clamp recordings of currents in cultured DIV10 MSN
were performed according to procedures described for SK-N-SH cells with
addition of 10 mM glucose to the extracellular solution.
YAC128 MSN Glutamate Toxicity Assay
The assay for glutamate-induced cell death was performed with primary WT
and YAC128 MSN as we previously described (Tang et al., 2005). The primary
cultures were established as described above. Test compounds were added
at 14 DIV to WT and YAC128 MSN cultures at the final concentration of
0.03 mM, 0.3 mM, and 3.0 mM from DMSO stocks as indicated. In parallel
control experiments the cultures were exposed to 1& DMSO. After 30 min
incubation with the test compounds, the MSN were exposed for 7 hr to
250 mMof glutamate added to the culture medium. Immediately after the treat-
ment with glutamate, neurons were fixed for 30 min in 4% formaldehyde plus
4%sucrose in PBS (pH7.4), permeabilized for 5min in 0.25%Triton X-100, and
stained by using the DeadEnd fluorometric TUNEL System (Promega). Nuclei
were counterstained with 5 mM of propidium iodine (PI) (Molecular Probes).
Coverslips were extensively washed with PBS and mounted in Mowiol 4-88
(Polysciences). Six to eight randomly chosen microscopic fields containing
100–300 MSN each were manually counted using Olympus IX70 fluorescent
microscope. The number of TUNEL-positive neuronal nuclei was calculated
as a fraction of PI-positive neuronal nuclei in each microscopic field. The frac-
tions of TUNEL-positive nuclei determined for each microscopic field were
averaged and the results are presented as means ± SE (n = number of fields
counted).
Dicer-mediated approach was used to achieve siRNA knockdown of
TRPC1 in primary MSN cultures by following described procedures (SupnetLtd All rights reserved
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systems (clone ID 8860600) and used as a PCR template to amplify
a 300 bp fragment (bp 2102–2401 in mouse TRPC1). T7 promoter sequence
was included in the sequence of both forward and reverse primers as follows:
FP = TAATACGACTCACTATAGGGTTCCTTCTCCAAAGA, RP = TAATACGAC
TCACTATAGGGTAGAAGTCCGAAAGC. The product of PCR reaction was
purified by NucleoSpin Extract II (Clontech) and dsRNA was obtained by T7
polymerase-mediated transcription for 16 hr at 37C (TurboScript T7 Tran-
scription Kit, Genlantis) followed by DNase I digestion for 15 min at 37C.
dsRNA was purified by lithium chloride precipitation and quantified using
NanoDrop 2000c (Thermo Scientific). Four microgram dsRNA and four units
of recombinant PowerCut Dicer enzyme (Finnzymes) were combined with
PowerCut Dicer Reaction Buffer in a total volume of 20 ml. After 16 hr at
37C, dsiRNA was purified on two consecutive RNA purification columns to
remove salts and free nucleotides. Described procedure yielded a size-homo-
geneous population <30 bp dsiRNA without contaminating long dsRNA.
Concentration of dsiRNA was determined by NanoDrop 2000c. The WT and
YAC128 MSN cultures were transfected on DIV2–4 by a mixture of 275 ng
siRNA-TRPC1 and 1 mM Accell fluorescently-labeled nontargeting siRNA
reagent (Thermo Scientific Dharmacon) using polyethylenimine (PEI) transfec-
tion reagent. The same amount of nontargeting siRNA reagent was used in
control transfections (Ctrl-siRNA). In both cases the neuronal transfection
efficiency was at least 80%, consistent with the previous studies (Supnet
et al., 2006). On DIV14, the MSNwere exposed for 7 hr to 250 mMof glutamate
added to the culture medium and then were fixed and permeabilized as
described above. The neurons were stained using In Situ Cell Death Detection
Kit, TMR red (Roche). Nuclei were counterstained with 3 mMof 40-6-diamidino-
2-phenylindole (DAPI). Six to eight randomly chosen microscopic fields con-
taining 100–300 MSN each were manually counted. The number of TUNEL-
positive neuronal nuclei was calculated as a fraction of DAPI-positive neuronal
nuclei in each microscopic field. The fractions of TUNEL-positive nuclei deter-
mined for each microscopic field were averaged and the results are presented
as means ± SE (n = number of fields counted).Statistical Analysis
All experiments were repeated for at least three times. Data were evaluated for
statistical significance by analysis using Sigma Plot t test or one-way ANOVA.
Statistical difference was considered to be significant only if p < 0.05.SUPPLEMENTAL INFORMATION
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